|
π
|
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
29 auth.
C. Fuchs,
T. Doi,
R. Jang,
K. Muro,
T. Satoh,
M. Machado,
Weijing Sun,
S. Jalal,
M. Shah,
J. Metges,
M. Garrido,
T. Golan,
M. MandalΓ ,
Z. Wainberg,
D. Catenacci,
...
A. Ohtsu,
K. Shitara,
R. Geva,
J. Bleeker,
A. Ko,
G. Ku,
P. Philip,
P. Enzinger,
Y. Bang,
D. Levitan,
Jiangdian Wang,
M. Rosales,
R. Dalal,
H. Yoon
|
10 |
2018 |
10
π
|
|
π
|
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
27 auth.
P. Johnson,
S. Qin,
Joong-Won Park,
R. Poon,
J. Raoul,
P. Philip,
Chih-Hung Hsu,
TsungβHui Hu,
J. Heo,
Jianming Xu,
Ligong Lu,
Y. Chao,
E. Boucher,
K. Han,
S. Paik,
...
J. Robles-AviΓ±a,
M. Kudo,
Lunan Yan,
A. Sobhonslidsuk,
D. Komov,
T. Decaens,
W. Tak,
L. Jeng,
David Liu,
R. Ezzeddine,
I. Walters,
A. Cheng
|
9 |
2013 |
9
π
|
|
π
|
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
7 auth.
Yiwei Li,
T. Vandenboom,
D. Kong,
Zhiwei Wang,
Shadan Ali,
P. Philip,
...
F. Sarkar
|
9 |
2009 |
9
π
|
|
π¦
|
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
15 auth.
P. Philip,
J. Benedetti,
C. Corless,
R. Wong,
E. OβReilly,
P. Flynn,
K. Rowland,
J. Atkins,
B. Mirtsching,
S. Rivkin,
...
A. Khorana,
B. Goldman,
C. Fenoglio-Preiser,
J. Abbruzzese,
C. Blanke
|
9 |
2010 |
9
π¦
|
|
π
|
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
29 auth.
M. Javle,
M. Lowery,
R. Shroff,
K. Weiss,
C. Springfeld,
M. Borad,
R. Ramanathan,
L. Goyal,
S. Sadeghi,
T. Macarulla,
A. El-Khoueiry,
R. Kelley,
I. Borbath,
S. Choo,
D. Oh,
...
P. Philip,
LiβTzong Chen,
T. Reungwetwattana,
E. Van Cutsem,
K. Yeh,
K. Ciombor,
R. Finn,
Anuradha Patel,
S. Sen,
D. Porter,
R. Isaacs,
A. Zhu,
G. Abou-Alfa,
T. Bekaii-Saab
|
9 |
2017 |
9
π
|
|
π’
|
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
14 auth.
E. OβReilly,
D. Oh,
N. Dhani,
D. Renouf,
Myung Ah Lee,
Weijing Sun,
G. Fisher,
A. Hezel,
Shao-chun Chang,
G. VlahoviΔ,
...
O. Takahashi,
Y. Yang,
D. Fitts,
P. Philip
|
8 |
2019 |
8
π’
|
|
π¦
|
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
10 auth.
P. Philip,
M. Mahoney,
C. Allmer,
James P. Thomas,
H. Pitot,
George P. Kim,
...
R. Donehower,
T. Fitch,
J. Picus,
C. Erlichman
|
8 |
2005 |
8
π¦
|
|
π
|
miR-146a suppresses invasion of pancreatic cancer cells.
7 auth.
Yiwei Li,
T. Vandenboom,
Zhiwei Wang,
D. Kong,
Shadan Ali,
P. Philip,
...
F. Sarkar
|
8 |
2010 |
8
π
|
|
π
|
Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.
9 auth.
Shadan Ali,
Aamir Ahmad,
Sanjeev Banerjee,
S. Padhye,
Kristin Dominiak,
J. Schaffert,
...
Zhiwei Wang,
P. Philip,
F. Sarkar
|
8 |
2010 |
8
π
|
|
π
|
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
21 auth.
M. Katz,
Q. Shi,
Syed A. Ahmad,
J. Herman,
R. Marsh,
E. Collisson,
L. Schwartz,
W. Frankel,
R. Martin,
W. Conway,
...
M. Truty,
H. Kindler,
A. Lowy,
T. Bekaii-Saab,
P. Philip,
M. Talamonti,
D. Cardin,
N. Loconte,
P. Shen,
J. Hoffman,
A. Venook
|
8 |
2016 |
8
π
|
|
π¬
|
Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.
Yiwei Li,
Fakhara Ahmed,
Shadan Ali,
P. Philip,
O. Kucuk,
F. Sarkar
|
8 |
2005 |
8
π¬
|
|
π¦
|
Phase II study of erlotinib in patients with advanced biliary cancer.
10 auth.
P. Philip,
M. Mahoney,
C. Allmer,
James P. Thomas,
H. Pitot,
George P. Kim,
...
R. Donehower,
T. Fitch,
J. Picus,
C. Erlichman
|
8 |
2006 |
8
π¦
|
